Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech: Q1 Earnings Snapshot

FBIO : 1.8000 (+2.27%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.8000 (+2.27%)
Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech: Q2 Earnings Snapshot

FBIO : 1.8000 (+2.27%)
Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech: Q1 Earnings Snapshot

FBIO : 1.8000 (+2.27%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.8000 (+2.27%)
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...

FBIO : 1.8000 (+2.27%)
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...

DERM : 5.21 (+1.17%)
FBIO : 1.8000 (+2.27%)
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics ...

FBIO : 1.8000 (+2.27%)
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...

FBIO : 1.8000 (+2.27%)
DERM : 5.21 (+1.17%)
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...

FBIO : 1.8000 (+2.27%)
DERM : 5.21 (+1.17%)

Barchart Exclusives

Up 77% YTD, This Cathie Wood Stock Could Have More Upside Potential
This crypto-focused stock just got a new bull note that has absolutely nothing to do with its crypto exposure. Should you invest? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar